Idelalisib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 801 publications
Targeting PI3Kδ for lymphoma and immune diseases treatment: a review.
Journal: Molecular diversity
Published: January 20, 2026
Integrated Transcriptomic and Secretome Proteomic Analysis of Hyperglycemia-Stimulated Endothelial Cells and Screening of Target Compounds.
Journal: Journal of visualized experiments : JoVE
Published: January 19, 2026
Drug-induced eosinophilic pneumonia: a real-world data mining study of the FAERS and Vigibase database reveals potential safety signals and risk patterns.
Journal: Frontiers in medicine
Published: January 15, 2026
Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy.
Journal: Hematological oncology
Published: December 17, 2025
Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.
Journal: Biochemical and biophysical research communications
Published: December 01, 2025
A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.
Journal: British journal of haematology
Published: November 13, 2025
Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia.
Journal: Current issues in molecular biology
Published: November 13, 2025
In Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia.
Journal: Toxicology and applied pharmacology
Published: October 16, 2025
Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status.
Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status.
Journal: Endocrinologia, diabetes y nutricion
Published: October 01, 2025
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
Journal: Journal of geriatric oncology
Published: September 26, 2025
Study on the Mechanism of Post-Chemotherapy Metastasis in Breast Cancer Based on Metabolomics and Development of TCM Metabolic Regulators.
Journal: Anti-cancer agents in medicinal chemistry
Published: September 01, 2025
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.
Journal: Molecular oncology
Published: September 01, 2025
Last Updated: 06/30/2026